{"filing":{"accession_number":"0001213900-26-077250","cik":"0001739174","ticker":"PHGE","company_name":"BiomX Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"ea0297633-8k_biomx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390026077250/ea0297633-8k_biomx.htm"},"events":[{"id":17411,"run_id":15586,"accession_number":"0001213900-26-077250","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The disclosure centers on a listing compliance issue: NYSE American advised that the Acquisition and Line of Credit trigger Section 712 stockholder approval requirements because the Conversion Shares equal 20% or more of outstanding shares. The Company cancelled 1,013,637 Conversion Shares on July 10, 2026 to regain compliance pending shareholder approval. While the underlying M\u0026A activity occurred earlier, this Item 8.01 disclosure is primarily a governance event—a shareholder approval requirement and listing compliance matter—rather than the M\u0026A activity itself (which was disclosed in the June 5 8-K).","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15867,"accession_number":"0001213900-26-077250","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on a listing compliance issue: NYSE American advised that the Acquisition and Line of Credit trigger Section 712 stockholder approval requirements because the Conversion Shares equal 20% or more of outstanding shares. The Company cancelled 1,013,637 Conversion Shares on July 10, 2026 to regain compliance pending shareholder approval. While the underlying M\u0026A activity occurred earlier, this Item 8.01 disclosure is primarily a governance event—a shareholder approval requirement and listing compliance matter—rather than the M\u0026A activity itself (which was disclosed in the June 5 8-K).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:15:46.854290+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15867,"accession_number":"0001213900-26-077250","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on a listing compliance issue: NYSE American advised that the Acquisition and Line of Credit trigger Section 712 stockholder approval requirements because the Conversion Shares equal 20% or more of outstanding shares. The Company cancelled 1,013,637 Conversion Shares on July 10, 2026 to regain compliance pending shareholder approval. While the underlying M\u0026A activity occurred earlier, this Item 8.01 disclosure is primarily a governance event—a shareholder approval requirement and listing compliance matter—rather than the M\u0026A activity itself (which was disclosed in the June 5 8-K).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:15:46.854290+00:00","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-07-10"}]}